We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessment of Interactions Between Methamphetamine and Aripiprazole - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00089440
Recruitment Status : Unknown
Verified July 2005 by National Institute on Drug Abuse (NIDA).
Recruitment status was:  Active, not recruiting
First Posted : August 6, 2004
Last Update Posted : January 11, 2017
Sponsor:
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to assess the interactions between intravenous methamphetamine and aripiprazole.

Condition or disease Intervention/treatment Phase
Amphetamine-Related Disorders Drug: Aripiprazole Phase 1

Detailed Description:
This is a double-blind, placebo-controlled human laboratory clinical pharmacology study to assess potential interactions between intravenous d-methamphetamine infusion and treatment with oral aripiprazole.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 17 participants
Primary Purpose: Treatment
Official Title: Assessment of Interactions Between IV Methamphetamine and Aripiprazole
Study Start Date : June 2004
Estimated Study Completion Date : March 2005

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions


Outcome Measures

Primary Outcome Measures :
  1. Adverse effect measures
  2. pharmacokinetic assessment

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must meet DSM-4 criteria for methamphetamine abuse or dependence and are non-treatment seeking.
  • Ability to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures.

Exclusion Criteria:

  • Please contact the site for more information.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00089440


Locations
United States, California
UCLA Integrated Substance Abuse Program
Los Angeles, California, United States, 90024
United States, New York
New York University, School of Medicine
New York, New York, United States, 10016
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Thomas Newton, M.D. University of California, Los Angeles
More Information

ClinicalTrials.gov Identifier: NCT00089440     History of Changes
Other Study ID Numbers: NIDA-MDS-0002-1
First Posted: August 6, 2004    Key Record Dates
Last Update Posted: January 11, 2017
Last Verified: July 2005

Additional relevant MeSH terms:
Amphetamine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Aripiprazole
Methamphetamine
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Stimulants
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Uptake Inhibitors